2020 Vault Rankings
At a Glance
“High-profile substantive work, excellent compensation, [and] awesome colleagues.”
“The partners I work for seek out and seem to value my work and view.”
“The pressures of trial—being away from home for extended periods, lifestyle changes, and such.”
About Wilkinson Walsh
Wilkinson Walsh is a high-stakes litigation firm headquartered in Washington, DC, with additional offices in Los Angeles and New York City. The firm can count its age on one hand, but it’s hardly a fledgling—Wilkinson Walsh has soared from the start, achieving success after success in the courtroom. Within two months of its founding, the firm had already won its first major trial, defeating a $1.5 billion class action on behalf of Philip Morris.
A 21st Century Firm
Wilkinson Walsh was founded in January 2016 by five former BigLaw litigators to focus on winning high-stakes trials. Based on the firm’s success in just its first four years, Benchmark Litigation has twice named Wilkinson Walsh the “Boutique Firm of the Year,” praising the firm as a “litigator’s dream shop.” Today, founding members Beth Wilkinson (former American Lawyer Litigator of the Year), Alexandra Walsh, and Brian Stekloff continue to lead the firm forward. The trio is joined by a formidable team of lawyers, including former federal prosecutors and former Supreme Court clerks.
Wilkinson Walsh’s experience includes antitrust, class actions, products liability, and sports matters. But the firm doesn’t box its lawyers into practice groups. According to the firm, it “can litigate any case, anytime, anywhere.” In just four short years, the firm’s lawyers have already tried more than 20 cases to verdict. Among the firm’s clients are such household names as Bayer, Facebook, FedEx, George-Pacific, Monsanto, the NCAA, the NFL, and Pfizer.
The firm also maintains a commitment to pro bono, with 90 percent of its lawyers taking on some type of pro bono work in the past year. Its work has included domestic violence, employment discrimination, and incarceration reduction—to name some.
The firm isn’t just focused on winning cases, however. It prides itself in “developing the next generation of trial lawyers.” And that means getting on your feet. Since the firm’s founding, nearly a quarter of its attorneys have served as first or second chair at trial. And attorneys are actively encouraged to gain stand-up experience through pro bono matters.
Similarly, the firm thinks outside the box when it comes to client needs, eschewing the typical billable model for individualized billing methods. The firm’s goal is to offer clients value and predictability when it comes to billing. Among the firm’s arrangements are monthly retainers, flat fees, and success-based fees.
News & Awards
Led by Brian Stekloff, Tamarra Matthews Johnson, and Rakesh Kilaru, we represented Monsanto in the first-ever federal court trial over allegations that the herbicide Roundup caused Non-Hodgkin’s Lymphoma. Wilkinson Walsh continues to lead both trial and MDL strategy for Monsanto in the litigation.
Led by partners Alex Walsh and Sean Eskovitz, Wilkinson Walsh won a decisive trial victory for Bayer in a $600 million certified consumer class action lawsuit brought on behalf of One A Day multivitamin consumers. Without calling any witnesses in the defense case, the team relied on Sean and Alex’s devastating cross-examinations to convince the jury to reject plaintiffs’ claims that Bayer had misrepresented the health benefits of One A Day multivitamins. Before trial, Wilkinson Walsh’s legal issues team, led by James Rosenthal and Kieran Gostin, cut the potential exposure by 85 percent from the $4 billion Plaintiffs had originally sought. The Wilkinson Walsh team was named “Legal Lions” by Law360 for the victory and received glowing praise from legal observers and media, including from Litigation Daily, Law360, Reuters, and American Healthcare Leader.
Led by Beth Wilkinson, Kieran Gostin, and Rakesh Kilaru, we were retained by Allergan to serve as sole trial counsel for Forest Laboratories in In re Namenda Direct Purchaser Antitrust Litigation, an antitrust class action in the Southern District of New York. Plaintiffs alleged that Forest had made an anticompetitive “reverse payment” and unlawfully attempted to effectuate a “hard switch” in connection with Namenda, a groundbreaking treatment for dementia in Alzheimer’s patients. After Wilkinson Walsh was retained, and on the eve of trial, the case settled for less than 5 percent of the claimed damages.
Led by Beth Wilkinson and Kosta Stojilkovic, Wilkinson Walsh represented John Kapoor, the founder of Insys Therapeutics, in a four-month criminal trial over allegations that Insys executives operated a nationwide racketeering conspiracy involving an FDA-approved opioid pain medicine called Subsys. Wilkinson Walsh is also handling post-trial proceedings, including winning a motion to acquit Dr. Kapoor on the government’s lead charges of illicit drug dealing and honest services fraud.
2001 M Street, NW
Washington, DC 20036
Phone: (202) 847-4000
Managing Partner: James Rosenthal
Total No. Attorneys 2020:
1 - 50
1st year: $190,000
2nd year: $200,000
3rd year: $220,000
4th year: $255,000
5th year: $280,000
6th year: $280,000
7th year: $305,000
8th year: $325,000
9th year: $340,000
Summer Associate: $190,000 (prorated)
Los Angeles, CA
New York, NY
Washington, DC (HQ)